Mesozeaxanthin protects the liver and reduces cardio-metabolic risk factors in an insulin resistant rodent model

References

• Eckel RH, Kahn R, Robertson RM, et al. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care. 2006;29:1697–10.
   PubMed Web of Science ®Google Scholar
• Mayans L. Metabolic syndrome: insulin resistance and prediabetes. FP Essent. 2015;435:11–16.
   PubMedGoogle Scholar
• Pereira MA, Kottke TE, Jordan C, et al. Preventing and managing cardiometabolic risk: the logic for intervention. Int J Environ Res Public Health. 2009;6:2568–2584.
   Web of Science ®Google Scholar
• Wycherley TP, Moran LJ, Clifton PM, et al. Effects of energy-restricted high-protein; low-fat compared with standard-protein; low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;96:1281–1298.
   PubMed Web of Science ®Google Scholar
• Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease: current status and future directions. J Dig Dis. 2015;16:541–557.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7:9127–9138.
   PubMed Web of Science ®Google Scholar
• Cerf ME. High fat programming of beta cell compensation; exhaustion; death and dysfunction. Pediatr Diabetes. 2015;16:71–78.
   Web of Science ®Google Scholar
• Zhao L, Zhong S, Qu H, et al. Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Sci Rep. 2015;5:10222.
   PubMed Web of Science ®Google Scholar
• Bone R, Landrum J, Alvarez-Correa C, et al. Macular pigment and serum response to dietary supplementation with meso-zeaxanthin. Invest Optom Vis Sci. 2003;44:405–405.
   Google Scholar
• Juturu V. Meso-Zeaxanthin (MZ): current perspectives and new insights. Adv Ophthalmol Vis Syst. 2014;4(1):00010.
   Google Scholar
• Firdous AP, Preethi KC, Kuttan R. Antioxidant potential of meso-zeaxanthin a semi synthetic carotenoid. Food Chem. 2010;119:1096–1101.
   Web of Science ®Google Scholar
• Nolan J, Meagher K, Kashani S, et al. What is meso-zeaxanthin; and where does it come from&quest. Eye. 2013;27:899–905.
   PubMed Web of Science ®Google Scholar
• Firdous AP, Sindhu ER, Kuttan R. Hepato-protective potential of carotenoid meso-zeaxanthin against paracetamol; CCl4 and ethanol induced toxicity. Indian J Exp Biol. 2011;49:44–50.
   PubMed Web of Science ®Google Scholar
• Nolan JM, Beatty S, Meagher KA, et al. Verification of meso-zeaxanthin in fish. J Food Sci Technol. 2014;5:335.
   Google Scholar
• Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939–1951.
   PubMed Web of Science ®Google Scholar
• Orhan C, Akdemir F, Tuzcu M, et al. Mesozeaxanthin protects retina from oxidative stress in a rat model. J Ocul Pharmacol Ther. 2016;32:631–637.
   PubMed Web of Science ®Google Scholar
• Johnson EJ, Hammond BR, Yeum KJ, et al. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am J Clin Nutr. 2000;71:1555–1562.
   PubMed Web of Science ®Google Scholar
• Karatepe M. Simultaneous determination of ascorbic acid and free malondialdehyde in human serum by HPLC-UV. LC GC North America. 2004;22:362–365.
   Web of Science ®Google Scholar
• Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–119.
   PubMed Web of Science ®Google Scholar
• Sahin K, Tuzcu M, Orhan C, et al. Anti-diabetic activity of chromium picolinate and biotin in rats with type 2 diabetes induced by high-fat diet and streptozotocin. Br J Nutr. 2013;110:197–205.
   Web of Science ®Google Scholar
• Clain DJ, Lefkowitch JH. Fatty liver disease in morbid obesity. Gastroenterol Clin North Am. 1987;16:239–252.
   PubMed Web of Science ®Google Scholar
• Thurnham DI, Howard AN. Studies on meso-zeaxanthin for potential toxicity and mutagenicity. Food Chem Toxicol. 2013;59:455–463.
   PubMed Web of Science ®Google Scholar
• Pessayre D. Role of mitochondria in non‐alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22:20–27.
   Web of Science ®Google Scholar
• Bhosale P, Bernstein PS. Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation. Biochim Biophys Acta. 2005;1740:116–121.
   PubMed Web of Science ®Google Scholar
• Martin HD, Jäger C, Ruck C. Anti and prooxidant properties of carotenoids. J Prakt Chem. 1999;341:302–308.
   Google Scholar
• Saravanan G, Ponmurugan P, Deepa MA, et al. Anti-obesity action of gingerol: effect on lipid profile; insulin; leptin; amylase and lipase in male obese rats induced by a high-fat diet. J Sci Food Agric. 2014;94:2972–2977.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Stahl W, Sies H, et al. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). Eur J Med Res. 2011;16:76–78.
   PubMed Web of Science ®Google Scholar
• Amengual J, Lobo GP, Golczak M, et al. A mitochondrial enzyme degrades carotenoids and protects against oxidative stress. Faseb J. 2011;25:948–959.
   PubMed Web of Science ®Google Scholar
• Morinobu T, Tamai H. Beta-carotene 15;15ʹ-dioxygenase activity in streptozotocin-induced diabetic rats. J Nutr Sci Vitaminol (Tokyo). 2000;46:263–265.
   Web of Science ®Google Scholar
• Lin C, Rountree CB, Methratta S, et al. Secondhand tobacco exposure is associated with nonalcoholic fatty liver disease in children. Environ Res. 2014;132:264–268.
   Web of Science ®Google Scholar
• Tobisch B, Blatniczky L, Barkai L. Cardiometabolic risk factors and insulin resistance in obese children and adolescents: relation to puberty. Pediatr Obes. 2015;10:37–44.
   PubMed Web of Science ®Google Scholar
• Seo DY, Lee S, Figueroa A, et al. Aged garlic extract enhances exercise-mediated improvement of metabolic parameters in high fat diet-induced obese rats. Nutr Res Pract. 2012;6:513–519.
   Web of Science ®Google Scholar
• Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8:923–934.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z. Pro-inflammatory cytokines in atherosclerosis. Isr Med Assoc J. 2008;10:529–530.
   Web of Science ®Google Scholar
• Jones JR, Barrick C, Kim KA, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA. 2005;102:6207–6212.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nair SA, Pillai MR. Biology of PPAR gamma in cancer: A critical review on existing lacunae. Curr Mol Med. 2007;7:532–540.
   PubMed Web of Science ®Google Scholar
• Naruhn S, Meissner W, Adhikary T, et al. 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist. Mol Pharmacol. 2010;77:171–184.
   PubMed Web of Science ®Google Scholar
• Singh SP, Schragenheim J, Cao J, et al. PGC-1 alpha regulates HO-1 expression; mitochondrial dynamics and biogenesis: role of epoxyeicosatrienoic acid. Prostaglandins Other Lipid Mediat. 2016;125:8–18. pii: S1098-8823(16)30051-X. DOI:10.1016/j.prostaglandins.2016.07.004.
   Web of Science ®Google Scholar
• Kowluru RA, Zhong Q, Santos JM, et al. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr Metab (Lond). 2014;11:8.
   Web of Science ®Google Scholar
• Kowluru RA, Menon B, Gierhart DL. Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rats. Invest Ophthalmol Vis Sci. 2008;49:1645–1651.
   PubMed Web of Science ®Google Scholar